JONATHAN LOCKHART: Open Payments
NPI 1679678403 · LONGVIEW, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$106,734 in 237 payments from 16 companies in 2025. Trend: 2023 $136,713 · 2024 $109,844 · 2025 $106,734
Speaker / faculty: $97,659Food & beverage: $4,644Travel & lodging: $4,275Education: $156
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 93 | $94,686 |
| E.R. Squibb & Sons, L.L.C. | 27 | $9,787 |
| Vanda Pharmaceuticals Inc. | 23 | $532 |
| Alkermes, Inc. | 18 | $404 |
| Teva Pharmaceuticals USA, Inc. | 9 | $222 |
| Lundbeck LLC | 12 | $185 |
| Axsome Therapeutics, Inc. | 13 | $164 |
| Otsuka America Pharmaceutical, Inc. | 14 | $160 |
| HARMONY BIOSCIENCES LLC | 4 | $157 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $152 |
Products named: VRAYLAR, COBENFY, FANAPT, REXULTI, ARISTADA, CAPLYTA, Auvelity, INGREZZA.
Industry payments across TX — which companies pay providers there.
